NEFL and Alzheimer disease: The combination of plasma Aβ42/Aβ40, p-tau217, and p-tau181 seems to be a potential non-invasive and cost-effective biomarker for diagnosing AD, while other individual markers like plasma p-tau181, NF-L, and BACE1 may be used as markers of disease progression and neurodegeneration.